Clinical Trial VICCPHI1040


A Phase I Study to Evaluate the Safety and Clinical Activity of WT1-A10+AS01B Antigen Specific Cancer Immunotherapeutic in Adult Patients with WT1-Positive Acute Myeloid Leukemia in Partial Remission with Incomplete Blood Count Recovery Post-Induction Therapy

Principal Investigator(s)

Stephen Strickland


  • Protocol No. VICCPHI1040
  • Open Date: 12/21/2010
  • Staging: Phase I
  • Age Group: Adults
  • Scope: National
  • Objective: To evaluate the severe toxicity and the clinical activity induced by WT1-A10 + AS01B in the specific patient population
  • Disease Sites: Phase I; Hematologic/Non-transplant
  • Therapies: Molecular Targeted Agents / Immunotherapy / Biologics
  • Drugs: WT1-A10 + AS01B ASCI
  • Participating Institutions: Vanderbilt University
  • National Clinical Trial ID: NCT01051063
  • Secondary Protocol No: 111727



Learn More

You do not have JavaScript enabled. This site works better with JavaScript turned on.